Izotropic Corporation Enters into Investor Relations Consulting Agreement and Grants Stock Option

Biotech & MedTech

July 3, 2019 (Source) – Izotropic Corp. (CSE: Symbol “IZO”) announces that it has entered into an investor relations consulting agreement with Mr. Robin Moriarty.

With nearly 40 years of investor relations and public company consulting experience, Moriarty has arranged in excess of $100M in financings, been a director of a public company, consistently increased market awareness for his clients, led investor relations teams, and proven to be results orientated in various sectors. Company management has worked with Moriarty in the past and welcomes an individual with his integrity and the ability to communicate professionally with investment communities and generate awareness.

The agreement term is for a period of 12 months commencing July 1, 2019, unless otherwise terminated as set forth in the IR agreement. Pursuant to the IR agreement, the consultant will provide various investor relations services to the company in exchange for aggregate consulting fees of $5,000 per month. In connection with this IR agreement the company has granted stock options to the consultant to acquire 200,000 common shares of the company at an exercise price of $0.36 cents per share for a period of one year from the date of grant. This stock option vests as of the date of grant.

On behalf of the Board of Directors

R.L Thast

About Izotropic Corp.

The company is engaged in the development and commercialization of next-generation, 3-D breast CT imaging technology for early diagnosis of breast cancer, that improves patient comfort, provides a true 360-degree-view acquisition and delivers high diagnostic accuracy.

The company has also established a wholly owned U.S subsidiary called Izotropic Imaging Corp in 2016 to advance the company’s breast imaging development.